Author:
Golino Ludovica,Caiazzo Marco,Diglio Pasquale,Tornincasa Espedito,Russo Gianmarco,Imperatore Francesco
Abstract
Levosimendan was used off label to treat two patients with similar clinical and medical history (severe COPD, bronchospasm, cigarette smoking, difficult weaning). Starting from these two favorable cases, an explorative review of the current literature was conducted relating to this use of Levosimendan and its rationale.
Reference9 articles.
1. Nieminen MS, Fruhwald S, Heunks LM, et al. Levosimendan: current data, clinical use and future development. Heart Lung Vessel 2013;5:227-45.
2. Pienkowski P, Voors AA, Anker SD, et al. ESC Scientific Document Group. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129-2200.
3. American Thoracic Society. Heart drug offers possible treatment for patients facing respiratory failure. ScienceDaily 2011. Available from: https://www.sciencedaily.com/releases/2011/09/110923095806.htm
4. Babik B, Balogh AL, Sudy R, et al. Levosimendan prevents bronchoconstriction and adverse respiratory tissue mechanical changes in rabbits. Am J Physiol Lung Cell Mol Physiol 2017;313:L950-L956.
5. Van Hees HW, Dekhuijzen PN, Heunks LM. Levosimendan enhances force generation of diaphragm muscle from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;179:41-7.